SomnoMed Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SOMNF research report →
Companysomnomed.com
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
- CEO
- Amrita Blickstead
- IPO
- 2010
- Employees
- 300
- HQ
- Crows Nest, NSW, AU
Price Chart
Valuation
- Market Cap
- $98.59M
- P/E
- -44.07
- P/S
- 0.96
- P/B
- 2.25
- EV/EBITDA
- 26.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 57.40%
- Op Margin
- 2.35%
- Net Margin
- -2.16%
- ROE
- -5.31%
- ROIC
- 4.55%
Growth & Income
- Revenue
- $111.49M · 21.65%
- Net Income
- $-3,456,329 · 71.77%
- EPS
- $-0.02 · 83.70%
- Op Income
- $3.62M
- FCF YoY
- 169.47%
Performance & Tape
- 52W High
- $0.51
- 52W Low
- $0.37
- 50D MA
- $0.49
- 200D MA
- $0.45
- Beta
- 0.84
- Avg Volume
- 5
Get TickerSpark's AI analysis on SOMNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SOMNF Coverage
We haven't published any research on SOMNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SOMNF Report →